KR20220016861A - 통풍 또는 고뇨산혈증의 치료약 - Google Patents

통풍 또는 고뇨산혈증의 치료약 Download PDF

Info

Publication number
KR20220016861A
KR20220016861A KR1020217040180A KR20217040180A KR20220016861A KR 20220016861 A KR20220016861 A KR 20220016861A KR 1020217040180 A KR1020217040180 A KR 1020217040180A KR 20217040180 A KR20217040180 A KR 20217040180A KR 20220016861 A KR20220016861 A KR 20220016861A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
administration
pharmaceutically acceptable
group
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217040180A
Other languages
English (en)
Korean (ko)
Inventor
시로 고바야시
에리 미야야마
마스하루 히라노
다카시 오타
Original Assignee
닛뽕 케미파 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닛뽕 케미파 가부시키가이샤 filed Critical 닛뽕 케미파 가부시키가이샤
Publication of KR20220016861A publication Critical patent/KR20220016861A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217040180A 2019-06-04 2020-06-04 통풍 또는 고뇨산혈증의 치료약 Pending KR20220016861A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2019-104534 2019-06-04
JP2019104534 2019-06-04
PCT/JP2020/022039 WO2020246528A1 (ja) 2019-06-04 2020-06-04 痛風又は高尿酸血症の治療薬

Publications (1)

Publication Number Publication Date
KR20220016861A true KR20220016861A (ko) 2022-02-10

Family

ID=73653292

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217040180A Pending KR20220016861A (ko) 2019-06-04 2020-06-04 통풍 또는 고뇨산혈증의 치료약

Country Status (8)

Country Link
US (1) US20220323441A1 (https=)
EP (1) EP3981469B1 (https=)
JP (2) JPWO2020246528A1 (https=)
KR (1) KR20220016861A (https=)
CN (1) CN113924145A (https=)
AU (1) AU2020287549B2 (https=)
CA (1) CA3149714A1 (https=)
WO (1) WO2020246528A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121648131A (zh) * 2020-12-08 2026-03-13 学校法人东日本学园 细胞内atp增强剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121153A1 (ja) 2004-06-14 2005-12-22 Nippon Chemiphar Co., Ltd. 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤
JP2016520133A (ja) 2013-05-31 2016-07-11 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
JP2019104534A (ja) 2017-12-13 2019-06-27 大日本印刷株式会社 ロール体梱包箱
JP2021127289A (ja) * 2018-04-27 2021-09-02 日本ケミファ株式会社 縮合ピリミジン誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121153A1 (ja) 2004-06-14 2005-12-22 Nippon Chemiphar Co., Ltd. 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤
JP2016520133A (ja) 2013-05-31 2016-07-11 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Arthritis Res Ther. 2009 ; 11 : R46
J Rheumatol 2004 ; 31 ; 2429-2432
페브릭 (등록 상표) 정 신청 자료 개요 [2011년 1월] ; 2.7.2 임상 약리 시험, P.30

Also Published As

Publication number Publication date
WO2020246528A1 (ja) 2020-12-10
AU2020287549B2 (en) 2026-01-29
CA3149714A1 (en) 2020-12-10
AU2020287549A1 (en) 2022-01-27
JP2025061775A (ja) 2025-04-11
EP3981469A1 (en) 2022-04-13
EP3981469B1 (en) 2024-11-20
JPWO2020246528A1 (https=) 2020-12-10
US20220323441A1 (en) 2022-10-13
EP3981469A4 (en) 2023-06-21
CN113924145A (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
KR101699912B1 (ko) 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
TWI564008B (zh) 難溶性藥物之溶解性改善製劑
JP7217890B2 (ja) 固体分散体
JP2025061775A (ja) 痛風又は高尿酸血症の治療薬
WO2012153313A1 (en) Pharmaceutical composition of febuxostat
CN116528840B (zh) 细胞内atp增强剂
JP6903252B2 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
HK40073463B (en) Therapeutic for gout or hyperuricemia
HK40073463A (en) Therapeutic for gout or hyperuricemia
HK40098529A (zh) 固体分散体
HK40027115B (zh) 固体分散体
HK40027115A (en) Solid dispersion
AU2006207396A1 (en) Medicament that is intended for oral administration, comprising a cyclooxygenase-2 inhibitor, and preparation method thereof
JP2008162949A (ja) チアゾリジンジオン化合物を含有する糖尿病治療薬

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000